Clinical trial · Observational
Patients With a Single, Small (2 cm or Less) Cancer Nodule in the Thyroid Gland Will be Offered Active Surveillance Initially for 5 Years. In Case of Cancer Growth or Changes in Ultrasonographic Appearance, Further Treatment Will be Offered.
Active Surveillance of Small Thyroid Cancers.
NCT07822217CI-TRIAL-00126363active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260917-000001
Summary
Brief summary (as posted)
Patients with a single, small (less than 2 cm) cancer nodule in the thyroid gland will be offered active surveillance initially for 5 years. In case of cancer growth or changes in ultrasonographic appearance, further treatment will be offered.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Active Surveillance | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Active surveillance
- description
- Above 30 years-of-age; one tumor suspicious for or diagnosed with malignancy (BSRTC V/VI); tumor 2 cm or less in widest diameter; cN0 and cM0.
Primary outcomes (1)
- measure
- Treatment
- timeFrame
- 24 months
- description
- The need for treatment due to tumor growth within 24 months (cumulative incidence)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
Show eligibility criteria text
Inclusion criteria: * age of 30 years or older AND * single, well-defined tumor in the thyroid gland, with a FNAB suspicious of cancer or diagnostic of cancer (category V or VI in the Bethesda system) AND * tumor size of 2 cm or less in all dimensions. Exclusion criteria: * suspicion of disseminated disease because of: * PET-positive lymph nodes on the neck * suspicious lymph-nodes by neck ultrasonography (US) * signs of capsular invasion of the tumor * suspicion of metastatic disease due to findings on PET-CT-scan or thoracic CT-scan; OR * tumor placement at a high-risk location (in the thyroid capsule or near the trachea) OR * previous thyroid surgery OR * concomitant hyperparathyroidism (ionized calcium \> 1.32 mmol/L and PTH \> 6 pmol/L) OR * if the patient is pregnant OR * If the patient is unable to give informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.